Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study.

BMJ Open Respir Res · 2024 · PMC11002339 · PMID 38575338

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

possibly not significantno p-value reported

For sotrovimab-treated patients, we also report a reduced risk of hospitalisation or death during BA.1 predominance and non-significant trends for reduced risk during BA.2 and BA.5, possibly not significant due to low event rate and small sample size for this comparison.

also in 22 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.